Quick Answer
GYRE THERAPEUTICS, INC. reported Total Revenue of $116.59 million for fiscal year 2025.
GYRE THERAPEUTICS, INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $116.59M +10.2% |
$105.76M -6.8% |
$113.45M +10.9% |
$102.29M +1294.0% |
$7.34M -65.0% |
$20.95M |
| Revenue (ASC 606) | $116.59M +10.2% |
$105.76M -6.8% |
$113.45M +10.9% |
$102.29M +1294.0% |
$7.34M -65.0% |
$20.95M |
| Net Income | $9.88M -44.8% |
$17.90M +120.9% |
-$85.48M -2081.5% |
$4.31M +104.9% |
-$87.93M -56.4% |
-$56.24M -1.9% |
| Diluted EPS | $0.02 -60.0% |
$0.05 +103.5% |
-$1.41 -4800.0% |
$0.03 +101.0% |
-$2.87 | — |
| Total Assets | $166.13M +32.5% |
$125.41M +7.6% |
$116.54M +37.5% |
$84.75M +52.3% |
$55.66M -41.3% |
$94.85M -3.8% |
| Cash and Equivalents | $37.07M +213.8% |
$11.81M -64.7% |
$33.51M +33.1% |
$25.18M -43.2% |
$44.35M +46.1% |
$30.36M +97.5% |
| Long-Term Debt | — | — | — | — | — | — |
| Stockholders Equity | $106.03M +67.5% |
$63.32M +500.0% |
-$15.83M -137.2% |
$42.52M +3.5% |
$41.09M -46.0% |
$76.07M +11.3% |
| R&D Expense | $13.70M +13.9% |
$12.02M -12.7% |
$13.78M | — | $68.89M +30.0% |
$52.98M +20.8% |
| Operating Income | $11.49M -28.9% |
$16.16M +124.0% |
-$67.23M -830.5% |
$9.20M +110.5% |
-$87.89M -53.2% |
-$57.37M -0.2% |
| Shares Outstanding | 91.31M +5.8% |
86.31M +12.7% |
76.60M +20.5% |
63.59M +102.4% |
31.41M +42.1% |
22.10M +83.5% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $30.56M | +19.9% | +14.2% |
| Revenue (ASC 606) | September 30, 2025 | $30.56M | +19.9% | +14.2% |
| Net Income | September 30, 2025 | $5.94M | +107.8% | +276.6% |
| Diluted EPS | September 30, 2025 | $0.03 | +200.0% | — |
| Total Assets | September 30, 2025 | $159.38M | +27.3% | +4.4% |
| Cash and Equivalents | September 30, 2025 | $40.40M | +154.6% | +10.7% |
| Long-Term Debt | March 31, 2014 | $142.0K | -84.5% | -49.8% |
| Stockholders Equity | September 30, 2025 | $101.92M | +61.3% | +10.8% |
| R&D Expense | September 30, 2025 | $2.36M | -14.8% | -31.0% |
| Operating Income | September 30, 2025 | $6.92M | +63.6% | +219.0% |
| Shares Outstanding | September 30, 2025 | 90.89M | +6.0% | +0.1% |
- GYRE THERAPEUTICS, INC. reported Total Revenue of $116.59 million for fiscal year 2025.
- GYRE THERAPEUTICS, INC. showed an increase of +10.2% in Total Revenue compared to the prior fiscal year.
- GYRE THERAPEUTICS, INC. reported Revenue (ASC 606) of $116.59 million for fiscal year 2025.
- GYRE THERAPEUTICS, INC. showed an increase of +10.2% in Revenue (ASC 606) compared to the prior fiscal year.
- GYRE THERAPEUTICS, INC. reported Net Income of $9.88 million for fiscal year 2025.
- GYRE THERAPEUTICS, INC. showed a decrease of -44.8% in Net Income compared to the prior fiscal year.
- GYRE THERAPEUTICS, INC. reported Diluted EPS of $0.02 per share for fiscal year 2025.
- GYRE THERAPEUTICS, INC. showed a decrease of -60.0% in Diluted EPS compared to the prior fiscal year.
- GYRE THERAPEUTICS, INC. reported Total Assets of $166.13 million for fiscal year 2025.
- GYRE THERAPEUTICS, INC. showed an increase of +32.5% in Total Assets compared to the prior fiscal year.
- GYRE THERAPEUTICS, INC. reported Cash and Equivalents of $37.07 million for fiscal year 2025.
- GYRE THERAPEUTICS, INC. showed an increase of +213.8% in Cash and Equivalents compared to the prior fiscal year.
- GYRE THERAPEUTICS, INC. reported Long-Term Debt of $283.0 thousand for fiscal year 2013.
- GYRE THERAPEUTICS, INC. showed a decrease of -75.1% in Long-Term Debt compared to the prior fiscal year.
- GYRE THERAPEUTICS, INC. reported Stockholders Equity of $106.03 million for fiscal year 2025.
- GYRE THERAPEUTICS, INC. showed an increase of +67.5% in Stockholders Equity compared to the prior fiscal year.
- GYRE THERAPEUTICS, INC. reported R&D Expense of $13.70 million for fiscal year 2025.
- GYRE THERAPEUTICS, INC. showed an increase of +13.9% in R&D Expense compared to the prior fiscal year.
- GYRE THERAPEUTICS, INC. reported Operating Income of $11.49 million for fiscal year 2025.
- GYRE THERAPEUTICS, INC. showed a decrease of -28.9% in Operating Income compared to the prior fiscal year.
- GYRE THERAPEUTICS, INC. reported Shares Outstanding of 91.31 million shares for fiscal year 2025.
- GYRE THERAPEUTICS, INC. showed an increase of +5.8% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: